Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thiotepa + carmustine
- Development stage
- Unknown
- Lead developer
- Washington University School of Medicine
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Thiotepa + carmustine is a high-dose chemotherapy conditioning regimen being evaluated by the Washington University School of Medicine for the treatment of high-risk diffuse large B-cell lymphoma (DLBCL). This combination is utilized as a conditioning step prior to autologous stem cell transplant (ASCT) specifically to prevent secondary central nervous system (CNS) relapse in patients who have achieved their first complete remission. Both thiotepa and carmustine are alkylating agents characterized by their ability to effectively cross the blood-brain barrier, a property that distinguishes this regimen from the standard BEAM (carmustine, etoposide, cytarabine, and melphalan) protocol. By targeting potential subclinical CNS disease, the regimen aims to reduce the high mortality associated with secondary CNS recurrence in high-risk systemic DLBCL populations.
- Other names
- thiotepa-based conditioningthiotepa/carmustine ASCTCNS-PHLAT regimen
02
Targets
DNAGSR (Glutathione reductase)
Beyond the preview
Go deeper on thiotepa + carmustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thiotepa + carmustine.